Occurrence of Brain Metastasis in Breast Cancer Patients Diagnosed at Advanced Stages of the Disease
A retrospective cohort study will be conducted in the Henry Ford Health System (HFHS). Using
medical record review, we will identify all women diagnosed with advanced stage (stage III
and IV) breast cancer between January 1, 1995- December 31, 2007. For each case included in
the study, we will obtain data on demographics, tumor information, treatment related medical
encounters and procedures, and occurrence and timing of brain and/or other distant
metastases. The main outcome for this study is the development of distant metastases. Each
patient in the cohort will be classified as to the occurrence and date of distant
metastases. Metastases will be classified as Brain, Distant lymph node, Lung/pleural
effusion, Liver, Bone, Other visceral, Other non-visceral.
Other secondary outcomes to be explored include:
- Survival after advanced breast cancer—time in months from the date of advanced stage
breast cancer diagnosis until death or end of study period
- Time to brain metastases—time in month from the date of advanced stage breast cancer
diagnosis until brain metastases diagnosis
- Survival after brain metastases—time in months from the date of diagnosis of brain
metastases until death or end of study period
Observational
Observational Model: Cohort, Time Perspective: Retrospective
Proportion of advanced stage breast cancer patients that develop brain metastases, overall and stratified by anti-HER2 therapy (for HER2+ patients only).
Time from breast cancer diagnosis until death or end of study periods (September 1, 2009)
No
GSK Clinical Trials
Study Director
GlaxoSmithKline
United Kingdom: GSK Observational Study
112951
NCT01077648
February 2010
June 2013
Name | Location |
---|